Transforming healthcare starts with the right people.

Ashraf Hanna is the chief operating officer of Verily. Previously he was the CEO of ORIC Pharmaceuticals, a company focused on the development of treatments for cancer resistance. Before that Ashraf spent nearly 11 years as a Vice President at Genentech leading the Commercial and Medical Affairs Finance functions, as well as Alliance Management and Portfolio Planning group, which is responsible for developing metrics and process for guiding R&D investments. Ashraf was also the CFO for the Genentech foundation, and previously at McKinsey and Company. He is a graduate of University of Chicago, has a Ph.D. in Physics from Harvard University and an M.D. from the University of Massachusetts.

Andrew Harrison is the Head of Business and Corporate Development. He and his team focuses on partnerships, collaborations, go-to-market activities, acquisitions, and Verily's venture capital activities. Andy started his career at RBC Ventures. Prior to Verily, Andy was a founding institutional investor and the Chief Operating Officer of Lapis Advisers, a healthcare-oriented investment firm. Prior to that, he was a senior partner at Fintan Partners, a firm originally capitalized by Stanford University's endowment which was acquired by Cantor Fitzgerald. Andy has degrees in bio-chemical and bio-medical engineering from McGill and Cornell University. He is a named inventor on medical device patents and is a CFA Charterholder. Andy currently represents Verily on a number of domestic and international boards.

Sheela leads Verily's global People Operations function overseeing HR, recruiting, talent programs, and operations. She brings more than 10 years of strategic experience in human resources, organizational growth and development, recruiting, and talent management. Sheela joined Verily as its first People Operations employee in late 2014, and prior to that she worked at Google. Sheela has a B.S. from Cornell University in Industrial and Labor Relations, and also studied International Relations and Law.

Vivian S. Lee, M.D., Ph.D., M.B.A., works closely with Verily's clinical and engineering teams to develop products and platforms that can support health system improvement and advance population health. Formerly, as dean, SVP and CEO, she led University of Utah Health, an integrated health system, academic campus, and health plan that has been recognized for its health care innovations and ranked first among university hospitals in quality and safety. As a healthcare executive and over her career as an NIH-funded MRI researcher, she has published a textbook and over 200 articles in leading journals including JAMA and New England Journal of Medicine. Vivian was elected to the National Academy of Medicine in 2015. A Rhodes Scholar, she is a graduate of Harvard-Radcliffe Colleges, Oxford University, Harvard Medical School, and NYU Stern School of Business.

As Chief Technical Officer, Brian pushes the frontier of medical device innovation at Verily, leading the company's discovery and rapid prototyping efforts. He joined Verily from the University of Washington Department of Electrical Engineering where he was an Associate Professor. Previously, Brian held positions at the University of Washington Kelly Tremblay Brain and Behavior Laboratory, the UC-Berkeley Ralph Freeman Neuroscience Lab, The Berkeley Wireless Research Center, Intel Corporation and Agilent Laboratories. He received his M.S. and Ph.D. in Electrical engineering in the field of low power integrated circuits for wireless sensors, from the University of California, Berkeley.

Jordi leads the Hardware and Medical Devices team at Verily, overseeing research and development of diagnostic and monitoring sensors, wearables, smart lenses, drug delivery devices, bioelectronics and other advanced medical technologies. Prior to joining Verily, Jordi spent 18 years in medical device research & development at companies including Advanced Bionics and Boston Scientific. Jordi is author of more than 60 distinct patent families with 200+ granted patents worldwide. He holds a B.S. degree in Physics from the Universitat Autònoma de Barcelona and B.S., M.S. and Ph.D. degrees in Electrical Engineering from the National Center for Microelectronics of Spain at the Universitat Autònoma de Barcelona.

Marti Taylor is the President and Chief Executive Officer of OneFifteen. An Ohio native, Marti started her career as a Staff Nurse at Duke University Hospital, where she ultimately spent 25 years and grew to oversee all aspects of the Health Systems Heart Center at 3 hospitals and multiple affiliated hospitals. Most recently, Marti served as CEO of University Hospital and the Ross Heart Hospital at The Ohio State University Wexner Medical Center. Marti earned her Bachelor of Science in Nursing from Capital University in Columbus, Ohio, and Master of Science in Nursing from Duke University in Durham, North Carolina.

Linus Upson joined Google in 2005 and is a vice president at Verily. He leads Verily's Debug Project and oversees engineering and user experience. Earlier he was responsible for overseeing Google's browser products including Chrome and Chrome OS. Prior to Google, Linus was an engineer at NeXT and Netscape and co-founded two companies, AvantGo and Qurb. Linus is on an extended leave from his undergraduate studies in mathematics at Princeton University.

Before leading communications and marketing at Verily, Carolyn was President of Brewlife, a W2O Group agency. There she focused on strategic branding and communications consulting for emerging brands, predominantly in life sciences and healthcare. Prior to Brewlife, Carolyn helped to build the digital health group within WCG, another W2O Group agency, where she led the healthcare practice. Carolyn received her B.S. in biology from Elon University.

Duncan joined Verily in 2014 and leads the finance team. Previously, Duncan worked in finance at YouTube with a focus on content licensing & partnerships. Prior to Alphabet, Duncan worked in private equity investing with Halyard Capital, a mid-market growth equity firm, and in investment banking at BMO Capital. Duncan completed his M.B.A. at Columbia Business School and graduated with a B.S. in Mechanical Engineering from Brown University.

Professor Tan Chorh Chuan was appointed the inaugural chief health scientist and executive director of the new Office for Healthcare Transformation in Singapore's Ministry of Health in January 2018. He was president of the National University of Singapore from 2008 to 2017. He previously served as director of Medical Services, Ministry of Health (2000-2004), where he led the public health response to the SARS epidemic. His awards include the National Science and Technology Medal (2008) and he was elected an international member of the US National Academy of Medicine in 2015. A renal physician, he obtained his medical training at National University of Singapore, and research training at the Institute of Molecular Medicine, Oxford.

Karen B. DeSalvo, M.D., M.P.H., M.Sc. is a physician whose career has been dedicated to improving the health of all people, with a particular focus on vulnerable populations, through patient care, education, policy and administrative roles, research, and public service. She is currently professor of Medicine and Population Health at the University of Texas at Austin Dell Medical School. Karen served as acting assistant secretary for Health and also the National Coordinator for Health Information Technology at the U.S. Department of Health and Human Services during the Obama Administration. She was previously New Orleans Health Commissioner and vice dean for Community Affairs and Health Policy at Tulane School of Medicine.

Kathy Giusti, a multiple myeloma patient, is the founder and chief mission officer of the Multiple Myeloma Research Foundation (MMRF) and serves on its board of directors. Kathy has led the MMRF in establishing collaborative research models in the areas of tissue banking, genomics, and clinical trials that are dramatically accelerating the pace at which life saving treatments are brought to patients. She also leads the Kraft Precision Medicine Accelerator, a $20M endowed program at Harvard Business School (HBS) that is developing business models to speed breakthroughs in precision medicine for all cancers. Kathy was ranked among Fortune magazine's "World's 50 Greatest Leaders" and listed as one of TIME magazine's "100 Most Influential People in the World." She received her M.B.A. from HBS and holds an honorary Doctorate from the University of Vermont.

Phil Nelson is a director of Engineering in Google Research. He joined Google in 2008 and was previously responsible for a range of Google applications and geo services. In 2013, he helped found and currently leads the Google Accelerated Science team that collaborates with academic and commercial scientists to apply Google's knowledge and experience running complex algorithms over large data sets to important scientific problems. Philip graduated from MIT in 1985 where he did award-winning research on hip prosthetics at Harvard Medical School. Before Google, Philip helped found and lead several Silicon Valley start-ups in search (Verity), optimization (Impresse), and genome sequencing (Complete Genomics) and was also an entrepreneur in residence at Accel Partners.

Steve N. Oesterle is a venture partner at NEA and serves as a senior advisor to EQT Partners and Temasek Holdings. He is currently a board director at Baxter International and Reva Medical. He was formerly SVP for Medicine and Technology at Medtronic, and a member of its Executive Operating Committee for 14 years. He oversaw long term internal technology investments while participating in strategic corporate investments in emerging private companies. He also served as a member of Medtronic's Business Development and Strategy Committee that approved all corporate acquisitions. During his tenure at Medtronic, Steve served on more than 20 boards as a director or observer. Steve graduated summa cum laude from Harvard and received his M.D. from Yale; he completed his residency at Massachusetts General Hospital. Following medical school, he completed a fellowship in Interventional Cardiology at Stanford and then served on the faculty at Stanford and Harvard Medical Schools and directed the Invasive Cardiology Services at Massachusetts General Hospital and Stanford.

During his decades-long career as a private sector healthcare technology leader, including as group executive VP for Optum, Andy Slavitt drove some of the most significant and successful initiatives in healthcare, impacting millions of Americans as well as the shape of the healthcare system. He was the former acting administrator of the Centers for Medicare and Medicaid Services under President Obama. Prior to that he was the group executive vice president of Optum, and before that a healthcare tech founder and entrepreneur. Andy is currently general partner at Town Hall Ventures and serves as board chair of United States of Care, a national non-profit health advocacy organization he founded. Andy leads a number of national health care initiatives, including one on the future of health care, which he co-chairs at the Bipartisan Policy Center. Today he is a highly recognizable voice in healthcare, with a regular column in the USA Today and regular appearances on CNN, MSNBC and Fox. Andy graduated from the College of Arts and Sciences and the Wharton School at the University of Pennsylvania and holds an M.B.A. from the Harvard Business School. He was recently named a Distinguished Policy Fellow at the University of Pennsylvania.

Daniel D. Von Hoff, M.D., F.A.C.P. is currently physician in chief, distinguished professor Translational Research Division at TGen (Translational Genomics Research Institute) in Phoenix, Arizona. He is also chief scientific officer for HonorHealth Clinical Research Institute and the Virginia G. Piper Distinguished Chair for Innovative Cancer Research. He is the medical director of research at McKesson Specialty Healthcare and the scientific medical officer for US Oncology Research and leader of the Translation Oncology Program (TOP) specializing in phase I clinical trials done in the US Oncology Research network. Daniel is also currently the Senior Consultant-Clinical Investigations for City of Hope. He also holds an appointment as professor of Medicine, Mayo Clinic, Scottsdale, AZ.